Kong Moonkyoo, Sung Ji-Youn, Lee Seung Hyeun
Division of Lung & Head and Neck Oncology, Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
Department of Pathology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
Onco Targets Ther. 2020 Aug 18;13:8173-8180. doi: 10.2147/OTT.S266344. eCollection 2020.
It has been reported that the overexpression of reactive oxygen species modulator 1 (Romo1) is significantly associated with poor survival outcomes in patients with lung cancer who received surgical resection, conventional fractionated radiotherapy, and chemotherapy. In this study, we investigated whether Romo1 expression is associated with survival outcomes in patients with early-stage lung cancer who were treated with radiosurgery.
Romo1 protein expression was evaluated and scored in the tumor tissue specimens of 40 patients with non-small cell lung cancer by immunohistochemistry. An optimal cut-off for Romo1 expression was determined and used to allocate patients to low or high Romo1 expression groups. Survival outcomes were compared between the two groups.
Romo1 expression was significantly associated with distant metastasis-free survival. The 1- and 2-year distant metastasis-free survival rates were 96.4% and 92.6% in the low Romo1 expression group and 87.5% and 46.7% in the high Romo1 expression group (P=0.041), respectively. The overall, local recurrence-free, regional recurrence-free, and disease progression-free survival rates were higher in the low Romo1 expression group than the high Romo1 expression group. However, the differences were not statistically significant.
Romo1 overexpression is associated with poor distant metastasis-free survival in patients with non-small cell lung cancer treated with radiosurgery. Further, large-scale prospective studies are required to identify the clinical efficacy of Romo1 as a potential adverse prognostic factor in lung cancer.
据报道，活性氧调节剂1（Romo1）的过表达与接受手术切除、常规分割放疗和化疗的肺癌患者的不良生存结果显著相关。在本研究中，我们调查了Romo1表达是否与接受放射外科治疗的早期肺癌患者的生存结果相关。
通过免疫组织化学对40例非小细胞肺癌患者的肿瘤组织标本进行Romo1蛋白表达评估和评分。确定Romo1表达的最佳临界值，并用于将患者分为Romo1低表达或高表达组。比较两组的生存结果。
Romo1表达与无远处转移生存期显著相关。Romo1低表达组1年和2年无远处转移生存率分别为96.4%和92.6%，高表达组分别为87.5%和46.7%（P=0.041）。Romo1低表达组的总生存期、无局部复发生存期、无区域复发生存期和无疾病进展生存期均高于高表达组。然而，差异无统计学意义。
Romo1过表达与接受放射外科治疗的非小细胞肺癌患者的不良无远处转移生存期相关。此外，需要大规模前瞻性研究来确定Romo1作为肺癌潜在不良预后因素的临床疗效。
